Suchergebnisse - "Rahman, Omar"

PubPharm (33)

1

Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line : A meta-analysis

enthalten in: The clinical respiratory journal | 2018

von Abdel-Rahman, O.

2

Radical multimodality therapy for malignant pleural mesothelioma

enthalten in: The Cochrane database of systematic reviews | 2018

von Abdel-Rahman, O. | Elsayed, Z. | Mohamed, H. | +1

3

Fatigue, alopecia and stomatitis among patients with breast cancer receiving cyclin-dependent kinase 4 and 6 inhibitors : a systematic review and meta-analysis

enthalten in: Expert review of anticancer therapy | 2017

von Lasheen, S. | Shohdy, K. | Kassem, L. | +1

4

Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib : a systematic-review and meta-analysis of the impact on survival

enthalten in: Expert review of gastroenterology & hepatology | 2017

von Abdel-Rahman, O. | Lamarca, A.

5

Evaluation of efficacy and safety of different pembrolizumab dose/schedules in treatment of non-small-cell lung cancer and melanoma : a systematic review

enthalten in: Immunotherapy | 2016

von Abdel-Rahman, O.

ErratumIn: Immunotherapy. 2017 Mar;9(4):373. - PMID 28303770

6

Risk of selected gastrointestinal and hepatic toxicities in cancer patients treated with nintedanib : a meta-analysis

enthalten in: Future oncology (London, England) | 2016

von Abdel-Rahman, O. | Bahie Eldin, N. | ElHalawani, H.

7

Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors : a meta-analysis

enthalten in: Therapeutic advances in respiratory disease | 2016

von Abdel-Rahman, O. | Fouad, M.

8

Correlation between PD-L1 expression and outcome of NSCLC patients treated with anti-PD-1/PD-L1 agents : A meta-analysis

enthalten in: Critical reviews in oncology/hematology | 2016

von Abdel-Rahman, O.

9

Rolapitant : a pooled analysis of its efficacy and safety in the prophylaxis of chemotherapy-induced nausea and vomiting

enthalten in: Future oncology (London, England) | 2016

von Abdel-Rahman, O. | Fouad, M.

10

Risk of elevated transaminases in non-small cell lung cancer (NSCLC) patients treated with erlotinib, gefitinib and afatinib : a meta-analysis

enthalten in: Expert review of respiratory medicine | 2016

von Abdel-Rahman, O. | Ahmed, H. | ElHalawani, H.